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Purpose/Objective: To evaluate patterns-of-care and patterns-of-
outcome after stereotactic body radiotherapy (SBRT) for stage I non-
small cell lung cancer (NSCLC). 
Materials and Methods: The working group 'Extracranial Stereotactic 
Radiotherapy' of the German Society of Radiation Oncology (DEGRO) 
performed a multi-center analysis of practice and outcome after SBRT 
for stage I NSCLC: 16 German and Austrian centers with experience in 
pulmonary SBRT were asked for participation. 
Results: Data of 582 patients treated in 13 institutions between 1998-
2011 were collected; all but one institution were academic hospitals. 
In 2010, the last full year covered in this analysis, 95 patients in total 
were treated with SBRT. The median number of patients per 
institution was 39 (range 8-110) and the median number of patients 
per institution and year was 5 (range 1-29). Median patient age was 72 
years (range 31-92) and median pre-treatment FEV1 was 58% (range 
16-129%). Median maximum tumor diameter was 2.5cm. NSCLC was 
biopsy confirmed in 84.5% of the patients. A time trend to more 
advanced radiotherapy technologies (nodal staging using FDG-PET, 
advanced type B dose calculation algorithm, in-room image guidance) 
was observed. The PTV encompassing dose was increased continuously 
and reached a plateau of 94Gy±26Gy BED (α/β=10Gy) on average in 
2006-2011. Patient characteristics (age, performance status, 
pulmonary function) remained stable over time. Inter-institutional 
variability was substantial in all treatment characteristics. In contrast, 
there was no inter-institutional variability in pre-treatment patient 
age and pulmonary function. After average follow-up of 21 months, 
three-years freedom from distant recurrence (FFDR), regional 
recurrence (FFRR) and local progression (FFLP) were 63.4%, 75.4% and 
79.6% for all 582 patients, respectively. Three-years overall survival 
(OS) was 47.1%. The biological effective dose (BED) was the most 
significant factor influencing all patterns of failure and OS in uni- and 
multivariate analysis. After ≥106Gy BED as planning target volume 
encompassing dose (n=164), three-years FFDR, FFRC, and FFLP were 
74.8%, 90.4% and 92.5%, respectively; three-years OS was 62.2%. The 
figure below shows OS depending on stage and irradiation dose. 
 
No evidence for a learning curve of improved results with larger SBRT 
experience or practice was observed. Radiation induced pneumonitis 
grade ≥2 was observed in 7.4% of the patients and grade 5 
pneumonitis was documented in only two patients.Thirty day 
mortality after SBRT was 0.5% (n=3). 
Conclusions: After irradiation doses ≥106Gy BED, favorable and 
consistent outcome after SBRT for stage I NSCLC was observed in this 
multi-institutional analysis despite substantial time-trends and inter-
institutional variability in the methodology of SBRT.  
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Purpose/Objective: Despite the increasing number of decision making 
tools, many are not used in daily clinical practice. Implementation 
might be stimulated if it is obvious that models can offer valuable 
extra information. We previously reported that prediction models 
outperformed physicians' predictions based on chart review. However, 
physically seeing a patient provides the doctor with extra information. 
The purpose of this prospective study was to compare predictions 
based on statistical models to predictions made by the physicians 
after they had seen the patient.  
Materials and Methods: Based on the performance of already pub-
lished and validated prediction models for lung cancer, we hypothe-
sized that these models would outperform the doctors prediction by 
at least 0.1 in Area Under the Curve (AUC) of the ReceiverOperating 
Characteristic (ROC). The required sample size for the primary out-
come, 2-yr survival, was 128 patients. Model predictions were ob-
tained and experienced radiation oncologists were asked to predict 2 
year survival,dyspnea (≥grade III) and dysphagia (≥grade III) at two 
time points: 1) after they had seen the patient for the first visit, and 
2) after the treatment plan was made. For survival prediction NSCLC 
patients,stage I-IIIB, were included;for dyspnea and dysphagia both 
NSCLC and SCLC were included. All patients were treated with radio-
therapy with or without chemotherapy, did not have surgery,no other 
tumor<5 years ago, and no distant metastasis. We compared the 
performance of the models to the doctors' in terms of AUC. To gain 
more insight in the benefit of using predictions in clinical practice we 
analysed the positive (PPV) and negative predictive value (NPV) for all 
possible cut-off values of the probabilities. In addition, Kaplan Meier 
curves based on TNMstage were made. 
 
 
Results:  At time point 1 the doctors predicted outcome for 121, 139 
and 146 patients (2-yr survival, dyspnea and dysphagia respectively). 
The AUCs of the doctors were 0.56, 0.59 and 0.52,while the models 
yielded AUCs of 0.71, 0.76 and 0.72, with p-values for difference in 
AUC of 0.02, 0.06 and 0.03 respectively. The Kaplan Meier curves 
based on TNM stage could not identify survival risk groups (p=0.33). 
Predictions at time point 2 were only available for 35,39 and 41 
patients (survival, dyspnea and dysphagia). Results were in line with 
those at time point 1. The PPVs of the models were generally higher, 
while the NPVs of doctors and models were comparable, indicating 
that the models could better identify high risk patients. 
Conclusions: Prediction models for lung cancer patients substantially 
outperformed the physicians' prediction for all outcomes. The differ-
ence between doctors and models did not decrease after the doctors 
had seen the treatment planning. The models were especially superior 
in identifying high risk patients and should therefore be implemented 
in clinical practice to guide decisions. 
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Purpose/Objective: Radiation induced toxicity is an important issue in 
head and neck cancer patients. With the introduction of IMRT into 
daily practice we are able to minimize doses to organs-at-risk while 
maintaining adequate tumor coverage. However, the commonly used 
elective nodal site doses might result in neck fibrosis and dysphagia. 
The goal of this randomized, multicenter trial was to investigate 
whether a reduction of the dose to the elective nodal sites and off-
target regions of the swallowing apparatus delivered by IMRT would 
result in a reduction of both acute and late side effects without 
compromising tumor control.  
Materials and Methods: Two-hundred patients with histologically 
proven head and neck squamous cell carcinoma were randomly 
assigned to the standard and experimental arm. In the standard arm 
the elective nodal volumes (PTVelective) were irradiated up to an 
equivalent dose of 50Gy in 2 Gy fractions. In the experimental arm an 
equivalent dose of 40Gy in 2 Gy fractions was delivered to the nodal 
volumes and the dose to the swallowing apparatus was kept as low as 
reasonably possible without compromising coverage of the therapeutic 
PTV (PTVther). Toxicity was recorded using CTCAE v3.0 weekly during 
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treatment and monthly up until 3 months after finishing treatment. 
Treatment outcome at 3 and 6 months was retrieved in 131 patients. 
A two-tailed Fisher’s Exact test was used to compare binary data 
between both arms. A Mann-Whitney U test was performed to 
compare continuous data.  
Results: Data of 193 patients could be retrieved (experimental arm: 
n=96 , standard arm: n= 97). No significant differences between both 
arms were seen in social status, age, sex, tumor site, smoking and 
alcohol abuse, TNM stage, performance stage, total dose delivered, 
overall treatment time and pretreatment dysphagia. Dosimetrically, 
no significant difference was seen between both arms concerning 
PTVther coverage (for D95: 67.5 Gy vs 67.3 Gy; p=0.9). As expected the 
median D95 of the PTVelect was significantly lower in the experimental 
arm than in the standard arm (39.5 Gy vs 49.8 Gy; p<0.0001). Using 
this strategy we were able to significantly reduce the dose to 
swallowing structures (Table 1). There was no significant difference in 
acute mucositis, skin toxicity and weight loss between both groups. 
During treatment no difference was seen in severe dysphagia. Three 
months after radiotherapy however there was significantly less grade 
3+ dysphagia in the experimental arm compared to the standard arm 
(2% vs 11%; p=0.03) (Figure 1). At 6 months, no significant difference 
was seen in locoregional control between both arms (88% vs 92%; 
p=0.6). 
Conclusions: Using IMRT we were able to significantly reduce the dose 
to the elective nodal volumes and several organs at risk without 
compromising PTVther coverage. This resulted in a significant reduction 
of severe dysphagia 3 months after radiotherapy, without 
compromising locoregional control. Further follow-up is necessary to 
investigate whether these observations translate into a benefit on late 
treatment related dysphagia without affecting treatment outcome.  
  
OC-0142   
Conventional radiotherapy vs. chemoradiotherapy vs. accelerated 
radiotherapy in advanced head neck cancer  
S. Ghosh Laskar1, J.P. Agarwal2, N. Kalyani2, A. Budrukkar2, T. Gupta2, 
V. Murthy2, M. Sengar3, D.A. Chaukar4, A.K. D' Cruz4 
1Tata Memorial Hospital, Radiation Oncology, Thane, India  
2Tata Memorial Hospital, Radiation Oncology, Mumbai, India  
3Tata Memorial Hospital, Medical Oncology, Mumbai, India  
4Tata Memorial Hospital, Surgical Oncology, Mumbai, India  
 
Purpose/Objective: To compare conventional fractionation 
radiotherapy (RT, Arm A), conventional fractionation RT with 
concurrent chemotherapy (CTRT, Arm B) and accelerated 
radiotherapy (ART, Arm C), in terms of survival and toxicity for loco-
regionally advanced, non-nasopharyngeal, Squamous Cell Carcinoma 
Head and Neck (HNSCC). 
Materials and Methods: Between April 2000 and October 2007, 179 
previously untreated, non metastatic, Stage III and IV HNSCC were 
randomised. There were 53, 64 and 62 patients in Arm A, B and C 
respectively. In arms A and B, all patients received conventional 
fractionation RT to a total dose of 66-70Gy in 6-7 weeks, five fractions 
per week. In Arm B, concurrent CT regimen consisted of Cisplatin 30 
mg/m2/week. In Arm C, the total dose of radiotherapy was same, 6 
fractions were administered per week, with concomitant boost being 
given on Saturday. Analysis was on an intention-to-treat basis. 
Results: The median age of cohort was 49 years. The age, sex, 
primary sites, stage of disease were equally distributed in all three 
arms. Oropharynx was the most common primary site in all the three 
arms. The median treatment duration was 49, 51 and 40 days in 3 
arms respectively. In arm B, the median number of chemotherapy 
cycles was 6. The mean and median follow up was 37.7 and 23 months 
respectively (Inter-quartile range 10-59 months). There was a 
significant difference in the Disease-Free Survival (DFS) and Overall 
survival (OS) for CT-RT arm compared with the others. The Median 
DFS in Arm A was 16 months compared to 34 months in Arm B and 10 
months in Arm C (p=0.02). Median OS in Arm A was 32 months 
compared to 76 months in Arm B and 32 months in Arm C (p=0.05). In 
terms of acute toxicities patients of Arm A experienced fewer Grade 3 
or more oral mucositis compared to Arms B & C (11 versus 22 versus 
19 respectively). No incidence of G3 or more haematological toxicity 
was seen during the treatment in either of the arms. There was no 
difference in acute grade 3 skin toxicity or significant sequelae 
between the arms (14 versus 15 versus 10 respectively). In terms of 
late toxicities (RTOG Scale) G2-G3 xerostomia was similar in all the 
three arms (10 versus 14 versus 11 respectively). Similarly the late 
toxicity in terms of skin, mucosa and subcutaneous tissue was similar 
in the 3 arms. Salvage surgery was done in 19 patients (4 versus 6 
versus 9 respectively in Arms A, B & C). Thirteen patients developed 
second primary cancer (3 versus 5 versus 5 respectively in Arms A, B & 
C). 
Conclusions: Concurrent CTRT is associated with significant better OS 
and DFS as compared to RT alone (Conventional or Accelerated) 
without significant increase in late toxicities.  
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Purpose/Objective: To assess the role of domiciliary based 
humidification (HUM) on the natural history of mucositis during 
radiotherapy (RT) for head and neck cancer. To evaluate the impact 
of HUM on patient reported outcomes (PRO). 
Materials and Methods: In this phase III multi-site trial, patients with 
SCC of the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx 
receiving definitive or adjuvant RT ± chemotherapy were randomised 
to either institutional standard of care (control) or HUM using the 
Fisher and Paykel Healthcare MR880 humidifier. HUM commenced day 
1 of RT and continued until CTCAE version 3.0 mucositis clinical exam 
score (CMuc) was <1. Compliance was recorded electronically. HUM 
Compliance ratio (HCR) was calculated using the formula: total days 
compliance > 4 hours from RT start to CMuc < grade 1 / total days 
from RT start to CMuc <grade 1. HCR of > 0.33 was set as the cutoff 
for the per protocol population analysis (PPA). CMuc was assessed 
weekly until week 12 or resolution of CMuc score < 1. The primary 
endpoint was the area under the curve (AUC) of CMuc grade >1. A 
credentialing programme promoted CMuc scoring consistency among 
investigators. The secondary endpoint CTCAE v 3.0 mucositis 
functional score (FSMuc) was analysed with similar methodology. PRO 
assessments included McMaster University Head and Neck 
Questionnaire (HRNQ) at baseline, 4, 7,12 and 20 weeks. Symptom 
cluster questions within HRNQ associated with mucositis analysed in 
addition to the normal HNRQ domains included severe cluster 
(difficulty tasting food, clearing secretions, swallowing or chewing) 
and moderate cluster (low energy, fatigue, dryness mouth, reduced 
appetite, pain mouth, pain throat, difficulty sleeping). The primary 
PRO comparison was the difference in means between the 2 arms at 
each timepoint. 
Results: 210 patients were randomised (control 105; HUM 105). There 
was no difference in AUC CMuc means for the intention to treat 
population (ITT): control 9.0 (95% CI; 8.1 – 10.0); HUM 8.9 (95% CI; 8.0 
–9.8); p 0.97. When patients with HCR < 0.33 were excluded for the 
PPA (60HUM patients; 58%), there was again no difference: control 9.0 
(8.1 – 10.0) HUM 7.8 (6.3 – 9.2) p 0.25. There was no difference in AUC 
FSMuc for ITT: control 9.6 (8.7 – 10.4) HUM 8.8 (8.0 – 9.5); p 0.22, but 
a significant difference for PPA: control 9.6 (8.7 – 10.4) HUM 7.7 (6.7 – 
8.7); p 0.009. For HNRQ ITT analysis, there was no difference in 
outcomes at any timepoint. The HNRQ PPA showed few significant 
differences but estimates were in the direction that favoured HUM 
with less symptom severity. 
Conclusions: There was no difference in the primary endpoint of AUC 
CMuc with HUM. There is a trend in the HNRQ PPA suggestive of 
efficacy with HUM which is reflected in the AUC FSMuc PPA as well but 
the major difficulties in achieving consistent patient compliance 
suggests this is not an effective therapy for mucositis in its current 
format.  
 
 SYMPOSIUM: MANAGEMENT OF BRAIN OLIGO-
METASTATIC DISEASE  
  
SP-0144   
Management of Brain Oligo-Metastastic Disease: The Dose Issue 
Perspective 
S.E. Combs1 
1Univ. Klinikum Heidelberg, Radiation Oncology, Heidelberg, Germany  
  
Treatment of patients with oligo-metastasic disease has moved into 
focus since it has been shown that limited disease volume and sites 
contribute favorably to outcome. This is also relevant in metastastic 
lesions to the brain. However, due to the dose-response relationship 
